Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwin Dreesen

Showing results (81-90 of 105) with videos related to

Pageof 11
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2018
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Bram Verstockt, Sumin Bian, et al.
Drugs & Aging|August 19, 2024
Decreased Kidney Function Explains Higher Vancomycin Exposure in Older AdultsAngela Elma Edwina, Erwin Dreesen, Matthias Gijsen, et al.
International Journal of Pharmaceutics|December 7, 2024
Tracking the journey: Gastrointestinal transit and intraluminal pH dynamics in aging populations using wireless motility capsuleAngela Elma Edwina, Mirko Koziolek, Nele Steenackers, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 9, 2025
Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn's DiseaseZhigang Wang, Yannick Hoffert, Wei Zhang, et al.
Journal of Crohn'S & Colitis|February 5, 2019
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission RatesBram Verstockt, Erwin Dreesen, Maja Noman, et al.
Clinical and Translational Science|June 19, 2026
European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and PerspectivesKonstantin Tachkov, Merita Rumano, James Bluett, et al.
Pediatric Research|October 11, 2024
Human serum albumin: prediction model and reference values for preterm and term neonatesZoë Vander Elst, Annouschka Laenen, Jana Deberdt, et al.
Mycoses|May 8, 2021
Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokineticsRuth Van Daele, Yves Debaveye, Robin Vos, et al.
Mycoses|April 19, 2022
Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU studyRuth Van Daele, Joost Wauters, Erwin Dreesen, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2021
Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenationRuth Van Daele, Roger J Brüggemann, Erwin Dreesen, et al.
Pageof 11

Showing results (81-90 of 105) with videos related to

Sort By:
Pageof 11
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2018
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Bram Verstockt, Sumin Bian, et al.
Drugs & Aging|August 19, 2024
Decreased Kidney Function Explains Higher Vancomycin Exposure in Older AdultsAngela Elma Edwina, Erwin Dreesen, Matthias Gijsen, et al.
International Journal of Pharmaceutics|December 7, 2024
Tracking the journey: Gastrointestinal transit and intraluminal pH dynamics in aging populations using wireless motility capsuleAngela Elma Edwina, Mirko Koziolek, Nele Steenackers, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 9, 2025
Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn's DiseaseZhigang Wang, Yannick Hoffert, Wei Zhang, et al.
Journal of Crohn'S & Colitis|February 5, 2019
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission RatesBram Verstockt, Erwin Dreesen, Maja Noman, et al.
Clinical and Translational Science|June 19, 2026
European Network on Optimizing Treatment With Therapeutic Antibodies in Chronic Inflammatory Diseases: Overview, Progress and PerspectivesKonstantin Tachkov, Merita Rumano, James Bluett, et al.
Pediatric Research|October 11, 2024
Human serum albumin: prediction model and reference values for preterm and term neonatesZoë Vander Elst, Annouschka Laenen, Jana Deberdt, et al.
Mycoses|May 8, 2021
Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokineticsRuth Van Daele, Yves Debaveye, Robin Vos, et al.
Mycoses|April 19, 2022
Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU studyRuth Van Daele, Joost Wauters, Erwin Dreesen, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2021
Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenationRuth Van Daele, Roger J Brüggemann, Erwin Dreesen, et al.
Pageof 11